PLXSPlexus Corp — stock analysis & sentiment

At $251.34, Plexus sits roughly in the middle-to-upper part of a wide 52-week band that runs from $125.92 to $307.06. That range means the stock has roughly doubled from its low to its high over the past year, a spread that points to a market repricing the business substantially over that window rather than trading in a narrow channel. The current level is about 18% below the high and roughly double the low.

The market is capitalizing the business at about $6.7 billion, or roughly 37 times trailing earnings and 25 times forward estimates — a gap that reflects expectations of higher earnings ahead. Price to book sits near 4.6. Underneath that, the reported profit margin is about 4.0%, which is thin in absolute terms and characteristic of contract manufacturing, where volume rather than markup drives results; revenue growth of roughly 28% is what the market appears to be weighing against that margin. A beta near 0.88 indicates the shares have historically moved somewhat less than the broad market.

Recent news flow is a mix of company items and sector-level material. The Plexus-specific headlines are largely procedural — investor conference appearances at Raymond James and Stifel, a fiscal 2023 sustainability report, and coverage of a Q2 earnings release that beat estimates while declining year over year, followed by a piece noting a 12.4% move since that report. The rest is contextual rather than about Plexus itself: a medical device contract manufacturing market forecast that touches its end markets, and two items unrelated to the company, including a connected-TV apps report that concerns the "Plex" streaming app rather than Plexus.